Aarti Drugs Limited

BSE:524348 Stock Report

Market Cap: ₹39.3b

Aarti Drugs Past Earnings Performance

Past criteria checks 1/6

Aarti Drugs's earnings have been declining at an average annual rate of -2%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 7.8% per year. Aarti Drugs's return on equity is 11.9%, and it has net margins of 6.4%.

Key information

-2.0%

Earnings growth rate

-1.6%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate7.8%
Return on equity11.9%
Net Margin6.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Aarti Drugs makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524348 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2423,7961,5221,0680
30 Jun 2424,2281,5681,0330
31 Mar 2425,2861,7141,0470
31 Dec 2326,5101,8021,0320
30 Sep 2327,0901,8021,0130
30 Jun 2327,5521,7949670
31 Mar 2327,1611,6639330
31 Dec 2226,6791,6568950
30 Sep 2226,3871,8728670
30 Jun 2225,3061,9108530
31 Mar 2224,8862,0508410
31 Dec 2122,9612,0148220
30 Sep 2121,9162,1118120
30 Jun 2121,9012,4388170
31 Mar 2121,5482,8048150
31 Dec 2021,0272,8768080
30 Sep 2020,4592,4747830
30 Jun 2019,4532,0447170
31 Mar 2018,0611,4147100
31 Dec 1918,1561,1007280
30 Sep 1917,2221,0317030
30 Jun 1915,9218886790
31 Mar 1915,6098986650
31 Dec 1814,1368636340
30 Sep 1813,6898876350
30 Jun 1813,4079436300
31 Mar 1812,4368236180
31 Dec 1711,5927906130
30 Sep 1711,3407355900
30 Jun 1711,5697215800
31 Mar 1711,9528185570
31 Dec 1612,1027855270
30 Sep 1611,8567765090
30 Jun 1611,4317134860
31 Mar 1611,3496874670
31 Dec 1511,1016867490
30 Sep 1511,0477447310
30 Jun 1511,1807744140
31 Mar 1510,9437733940
31 Dec 1410,8688076900
30 Sep 1410,4907216790
30 Jun 1410,1096626710
31 Mar 149,6996086570
31 Dec 139,0835265760

Quality Earnings: 524348 has high quality earnings.

Growing Profit Margin: 524348's current net profit margins (6.4%) are lower than last year (6.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524348's earnings have declined by 2% per year over the past 5 years.

Accelerating Growth: 524348's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 524348 had negative earnings growth (-15.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.4%).

Return on Equity

High ROE: 524348's Return on Equity (11.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 09:25
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aarti Drugs Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rashmi Sancheti ShettyCGS International
Rashmi Sancheti ShettyDolat Capital Market Pvt. Ltd.
Kameswari V. S. ChavaliFirstCall Research